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Abstract
Introduction The major histocompatibility complex (H-2d) and
non-major histocompatibility complex genetic backgrounds
make the BALB/c strain highly susceptible to inflammatory
arthritis and spondylitis. Although different BALB/c colonies
develop proteoglycan-induced arthritis and proteoglycan-
induced spondylitis in response to immunization with human
cartilage proteoglycan, they show significant differences in
disease penetrance despite being maintained by the same
vendor at either the same or a different location.
Methods BALB/c female mice (24 to 26 weeks old after 4
weeks of acclimatization) were immunized with a suboptimal
dose of cartilage proteoglycan to explore even minute
differences among 11 subcolonies purchased from five different
vendors.  In vitro-measured T-cell responses, and serum
cytokines and (auto)antibodies were correlated with arthritis
(and spondylitis) phenotypic scores. cDNA microarrays were
also performed using spleen cells of naïve and immunized
BALB/cJ and BALB/cByJ mice (both colonies from The Jackson
Laboratory, Bar Harbor, ME, USA), which represent the two
major BALB/c sublines.
Results The 11 BALB/c colonies could be separated into high
(n = 3), average (n = 6), and low (n = 2) responder groups
based upon their arthritis scores. While the clinical phenotypes
showed significant differences, only a few immune parameters
correlated with clinical or histopathological abnormalities, and
seemingly none of them affected differences found in altered
clinical phenotypes (onset time, severity or incidence of arthritis,
or severity and progression of spondylitis). Affymetrix assay
(Affymetrix, Santa Clara, CA, USA) explored 77 differentially
expressed genes (at a significant level, P < 0.05) between The
Jackson Laboratory's BALB/cJ (original) and BALB/cByJ
(transferred from the National Institutes of Health, Bethesda,
MD, USA). Fourteen of the 77 differentially expressed genes
had unknown function; 24 of 77 genes showed over twofold
differences, and only 8 genes were induced by immunization,
some in both colonies.
Conclusions Using different subcolonies of the BALB/c strain,
we can detect significant differences in arthritis phenotypes,
single-nucleotide polymorphisms (SNPs), and a large number of
differentially expressed genes, even in non-immunized animals.
A number of the known genes (and SNPs) are associated with
immune responses and/or arthritis in this genetically arthritis-
DDA: dimethyldioctadecyl-ammonium bromide; ELISA: enzyme-linked immunosorbent assay; IFN-γ: interferon-gamma; IL: interleukin; IVD: interverte-
bral disc; MHC: major histocompatibility complex; NCI: National Cancer Institute (Bethesda, MD, USA); NIH: National Institutes of Health (Bethesda, 
MD, USA); PG: proteoglycan; PGIA: proteoglycan-induced arthritis; PGIS: proteoglycan-induced spondylitis; QTL: quantitative trait locus; RA: rheu-
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prone murine strain, and a number of genes of as-yet-unknown
function may affect or modify clinical phenotypes of arthritis and/
or spondylitis.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
that leads to inflammatory cartilage destruction and bone ero-
sion in synovial joints. Although the pathological mechanism of
RA is unknown, both environmental and genetic factors are
thought to be involved in the etiology and pathogenesis of the
disease [1]. Animal models, especially those that involve joint
pathology in genetically altered rodents, are invaluable aids in
the research of human autoimmune diseases [2-6]. Among the
systemic animal models of RA, cartilage proteoglycan (PG)
aggrecan-induced arthritis (PGIA) is a T cell-dependent and
autoantibody/B cell-mediated disease in BALB/c mice which
is frequently accompanied by spondylitis [7-10]. In addition to
the major histocompatibility complex (MHC), PGIA and PG-
induced spondylitis (PGIS) are controlled by multiple genetic
loci [9,11]. Although various non-MHC genetic loci (quantita-
tive trait loci; QTLs) may contribute to disease, different com-
binations of these QTLs may result in a remarkably uniform
clinical phenotype of arthritis [12].
Due to a specific genetic background, the BALB/c strain
shows a strong predisposition toward arthritis. In addition to
PGIA, immunization with cartilage link protein [13] or human
cartilage glycoprotein-39 (HC-gp39) [14] can induce arthritis,
but only in BALB/c mice. Moreover, interleukin-1 (IL-1) recep-
tor antagonist protein-deficient mice [15] and SKG mice, in
which a spontaneous point mutation occurred in ZAP-70,
develop spontaneous arthritis [16], both only in the BALB/c
background.
Despite the efforts of companies to maintain genetically
homogenous inbred colonies, there are differences among
BALB/c colonies/substrains (for example, in body weight, size
of littermates, and the composition of intestinal bacterial flora)
maintained at different locations by the same vendor. Accord-
ing to the online public database of The Jackson Laboratory
(Bar Harbor, ME, USA) [17], there are at least 492 single-
nucleotide polymorphism (SNP) differences between their two
inbred BALB/cJ and BALB/cByJ colonies; of these, at least 59
SNPs are present in 33 immune-regulatory genes in the
mouse genome (F. Boldizsar and T.T. Glant, unpublished in
silico analysis data). Some of these known, or as-yet-unknown,
mutations may significantly influence the pathogenesis and
progression of PGIA or PGIS.
Since we have 'simplified' the model by replacing the highly
purified human fetal cartilage PG [7,18] with PG isolated from
human osteoarthritic cartilage [19,20] and changed the Fre-
und's adjuvants to a synthetic adjuvant [21], the PGIA/PGIS
model became available to a wide range of applications,
including the testing of new pharmacological agents. How-
ever, we and others observed differences in the onset, inci-
dence, and severity of arthritis, even when the source of
antigen (for example, our laboratory) and immunization proto-
cols were the same. Therefore, either local environmental com-
ponents or the source of BALB/c colony might account for the
different levels of susceptibility to, or severity of, PGIA.
Because environmental factors also play critical roles in RA
susceptibility [22] and different BALB/c colonies may have dif-
ferent panels of spontaneous mutations, it has become neces-
sary to test these components under uniform conditions. In the
present study, we investigated the disease parameters (onset
time, susceptibility, severity, and progression) simultaneously
in various colonies of BALB/c mice in the same experimental
setup. Because the BALB/c strain is highly susceptible to
PGIA (and PGIS) and sooner or later all immunized animals
develop arthritis independently of the colony source, we used
a suboptimal dose of PG antigen to be able to monitor even
minute differences among the colonies.
Materials and methods
Chemicals, antigen, animals, and immunization of mice 
with cartilage proteoglycan aggrecan
All chemicals, unless otherwise indicated, were purchased
from Sigma-Aldrich (St. Louis, MO, USA) or Fischer Scientific
Co. (Chicago, IL, USA). Mouse-specific cytokine enzyme-
linked immunosorbent assay (ELISA) kits were purchased
from R&D Systems (Minneapolis, MN, USA) or BD Bio-
sciences (San Jose, CA, USA). Cartilage specimens from
knee joints were obtained from osteoarthritic patients under-
going joint replacement surgery. The use of human cartilage
for PG isolation was approved by the Institutional Review
Board of Rush University Medical Center (RUMC) (Chicago,
IL, USA). PG isolation has been described in detail [19,20]. All
animal experiments were approved by the Institutional Animal
Care and Use Committee of RUMC. Animals were maintained
in a pathogen-free environment in the same room and rack. A
total of 178 (retired breeder) female BALB/c mice of 11 colo-
nies (Table 1) were ear-tagged, and registered mice (all 24 to
26 weeks old) were randomly mixed and left for acclimatization
to the local environment for 4 weeks prior to the first immuni-
zation.
Mice were injected intraperitoneally with a 'suboptimal' dose
of human cartilage PG aggrecan (equivalent to 75 μg, instead
of the 'standard' dose of 100 μg of core protein of PG) emul-
sified with 2 mg of dimethyldioctadecyl-ammonium bromide
(DDA) adjuvant in 200 μL of phosphate-buffered saline (pHAvailable online http://arthritis-research.com/content/11/1/R21
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7.4). DDA is a synthetic adjuvant with positively charged
micelle-forming hydrophobic-hydrophilic (detergent-like) prop-
erties and does not contain mineral oil or mycobacterial com-
ponents as Freund's adjuvants do [21]. Intraperitoneal
injections were given on days 0, 21, and 42 of the experiment,
and mice were sacrificed on days 63 and 64. The goal of using
a suboptimal dose of cartilage PG aggrecan was necessary;
otherwise, all animals develop arthritis with a high arthritis
score after the third PG aggrecan (100 μg) injection in DDA
[20,21]. About half a year later, these experiments were
repeated using BALB/cJ and BALB/cByJ strains (The Jackson
Laboratory) and Portage P08 and Hollister H42 (Charles River
Laboratories, Inc., Wilmington, MA, USA) as well as National
Cancer Institute (NCI) (Bethesda, MD, USA) (Kingston)
BALB/c colonies (10 to 15 animals per group).
Clinical and histological assessment of arthritis and 
spondylitis
Arthritis severity was determined using a visual scoring system
based on the degree of swelling and redness of the front and
hind paws [7,18,20]. Animals were examined at least three
times a week and inflammation was scored from 0 to 4 for
each paw, resulting in a cumulative arthritis score ranging from
0 to 16 for each animal [7,20]. To monitor early inflammatory
reactions as well, in this particular study, an acute arthritis
score of 0.5 was given if at least two interphalangeal, meta-
carpo-phalangeal, or metatarso-phalangeal joints were swol-
len but the paw inflammation (swelling and redness) did not
reach the 'standard' level of an arthritis score of 1 [20]. Ani-
mals were scored alternatively by two investigators in a blind
manner. Incidence of the disease was expressed as the per-
centage of arthritic mice to the total number of PG-immunized
mice per colony. Acute arthritis (severity) score was applied
only to arthritic animals. In addition, an arbitrary score (from 5
to 0) from the earliest onset of arthritis (onset score of 5) to
negative (onset score of 0) was established for each mouse
[23,24]. This onset score represents how quickly a mouse
developed arthritis.
Upon sacrifice, limbs and spines were removed, fixed in 10%
formalin, acid-decalcified, and processed in accordance with
standard histological procedures [7-9,20]. A total of 2,298
intervertebral discs (IVDs) of 127 spines (7 to 15 per colony)
were examined and scored. A modified histological scoring
system of the spine [10] was established by assessment of the
severity of spine involvement, which may achieve a score for
each IVD, ranging from 0 to 8. No inflammation was scored as
0, inflammatory (leukocyte) cell accumulation (peridiscitis and
Table 1
Arthritis susceptibility, severity, and onset of different BALB/c colonies
Colonya Vendors Arthritic/total number of animals Arthritis score (acute)b Onset scorec
Number Symbol Incidence Percentage
1 ● Portage P08; Charles River Laboratories, Inc. 
(Wilmington, MA, USA)
16/16 100% 11.0 ± 1.1 2.3 ± 0.3
2 ● Canada II; Charles River Laboratories, Inc. 15/15 100% 10.3 ± 1.3 2.5 ± 0.4
3 ● Harlan Laboratories, Inc. (Indianapolis, IN, USA) 12/13 92% 9.7 ± 1.5 2.8 ± 0.5
4 ■ Kingston K72; Charles River Laboratories, Inc. 13/14 93% 8.8 ± 1.2 2.1 ± 0.4
5 ■ Raleigh R02; Charles River Laboratories, Inc. 15/15 100% 7.6 ± 1.0 1.9 ± 0.3
6 ■ Taconic Farms, Inc. (Hudson, NY, USA); Charles 
River Laboratories, Inc.
15/18 83% 7.5 ± 1.4 1.6 ± 0.3
7 ■ NCI/Kingston (Charles River Laboratories, Inc.) 17/20 85% 6.8 ± 0.9 1.5 ± 0.2
8 ■ BALB/cJ; The Jackson Laboratory 
(Bar Harbor, ME, USA)
16/19 84% 6.6 ± 1.1 2.1 ± 0.3
9 ■ Raleigh R12; Charles River Laboratories, Inc. 10/13 77% 6.4 ± 1.5 1.2 ± 0.2
10 ▲ Hollister H42; Charles River Laboratories, Inc. 10/15 67% 3.8 ± 0.8 1.1 ± 0.2
11 ▲ Bailey's BALB/c ByJ; The Jackson Laboratory 15/20 75% 2.4 ± 0.7 1.0 ± 0.2
All animals were immunized with human cartilage proteoglycan aggrecan in dimethyldioctadecyl-ammonium bromide. Values represent mean ± 
standard error of the mean. aColony numbers indicate the different BALB/c colonies. bHighest arthritis score measured at any time point of the 
experiment. cOnset score was calculated at the end of the experiment (days 63 and 64) and ranged from the earliest onset of inflammation (5) to 
no arthritis (0). Circles (●) represent the most arthritis-prone colonies. Designation was based on the statistical analysis showing no significant 
differences between these three colonies (1 to 3) comparing two major clinical variables: onset and severity. Therefore, these three colonies were 
combined and designated as group I (Figure 1a). Squares (■) indicate the average clinical phenotype of arthritis (colonies 4 to 9) with no 
significant differences using onset and severity scores as clinical phenotype markers. This combined group is designated as group II (Figure 1a). 
Triangles (▲) represent the two least arthritic or least susceptible colonies, 10 and 11. Data of these two colonies were combined, and the two 
colonies together were designated as group III (Figure 1a). NCI, National Cancer Institute (Bethesda, MD, USA).Arthritis Research & Therapy    Vol 11 No 1    Farkas et al.
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enthesitis) was scored as 1 or 2, progression of IVD resorption
was scored as 3 to 6, fibrotic or fibro-cartilaginous ankylosis
(with complete disc resorption) received a score of 7, and
complete ankylosis due to chondrophyte/osteophyte forma-
tion was scored as 8. A cumulative spodyloarthropathy score
(the sum of spondylitis scores per spine) was calculated for
each animal.
Measurements of serum cytokines and anti-
proteoglycan antibodies and the lymphocyte responses
Serum cytokines IL-1β, IL-4, IL-6, interferon-gamma (IFN-γ),
and tumor necrosis factor-alpha were measured by ELISA.
Antigen-specific lymphocyte responses were measured in
spleen cell cultures in the presence or absence of 50 μg/mL
human PG antigen. Antigen-specific IL-2 production was
measured as a proliferative response of CTLL-2 cells to IL-2 in
48-hour spleen cell supernatants (CTLL-2 bioassay) [20].
Lymphocyte proliferation was assessed on day 5 of culture by
measuring [3H]-thymidine incorporation [18,20], and antigen-
specific T-cell proliferation was expressed as stimulation index
[7,18,20]. In vitro production of the above-listed cytokines
was also measured in supernatants of antigen (PG)-stimulated
(50  μg/mL) spleen cell cultures on day 5 using ELISA.
Secreted cytokine concentrations were normalized to nano-
grams per million cells [9,11].
PG-specific serum antibodies were measured by ELISA using
at least three different serum dilutions. Highly purified human
or mouse cartilage PG [25] was immobilized onto the surface
of Nunc-Maxisorp 96-well plates (Nalge Nunc, Naperville, IL,
USA) [20]. For PG-specific IgG isotype assays, peroxidase-
labeled goat anti-mouse IgG1 (Zymed Laboratories, Inc., now
part of Invitrogen Corporation, Carlsbad, CA, USA) and IgG2a
(BD Biosciences) were employed. Serum PG-specific anti-
body levels were calculated using serial dilutions of pooled
and standardized sera of mice with PGIA [20].
Affymetrix hybridization and related statistical analysis
RNA samples from spleen cells of naïve and immunized (12
days after the intraperitoneal PG injection) mice were
extracted with TriReagent (Sigma-Aldrich) in accordance with
the instructions of the manufacturer. Affymetrix hybridization
(Affymetrix, Santa Clara, CA, USA) was performed using
'Mouse Genome 430 2.0' gene chips. Biotinylation of cRNA,
labeling, and hybridization were processed by the Genomic
Core Facility of the University of Illinois at Chicago. Data were
analyzed using the GeneSpring GX 10.0 software package
(Agilent Technologies, Inc., Santa Clara, CA, USA). Robust
multi-array average [26] summarization algorithm (with quan-
tile normalization and median polish probe summarization pro-
cedures) and baseline transformation (that is, per gene
normalization; baseline to median of all 12 samples) were run
on data using a logarithmic scale. All sample replications
passed quality control. For pairwise comparisons, the Stu-
dent-Newman-Keuls post hoc test was performed after one-
way analysis of variance on four groups (naïve BALB/cJ, naïve
BALB/cByJ, immunized BALB/cJ, and immunized BALB/cByJ)
to identify statistically significant (P  < 0.05) differentially
expressed transcripts and statistical differences between
naïve and immunized mice of the two colonies. Asymptotic P
value computation and Benjamini-Hochberg false discovery
rate multiple testing correction were applied [27]. Hierarchical
clustering was applied to significantly differentially expressed
genes, based on the Pearson centered distance metric and
centroid linkage rule. Differentially expressed transcripts were
annotated with the GeneSpring software. The bivariate linear
correlation (Pearson) test was performed to identify statistical
correlations among spine and arthritis parameters. The Fisher
exact chi-square test was applied when normal and diseased
animals were compared. These statistical analyses were per-
formed using SPSS version 16.0 statistical software (SPSS
Inc., Chicago, IL, USA).
Results
Susceptibility, severity, and onset of arthritis in different 
BALB/c colonies
Based on the visual scoring system [20] and later confirmed
by histology, we could sort the 11 BALB/c colonies into three
major groups. There were no statistical differences in arthritis
severity and onset time within any of the three groups (Table 1
and Figure 1a). Overall, arthritis scores ranged from 2.4 ± 0.7
to 11.0 ± 1.1 and the onset score of arthritis ranged from 1.0
± 0.2 to 2.8 ± 0.5 (Table 1). Most of the BALB/c colonies (col-
ony numbers 4 to 9, henceforth called group II) developed
arthritis at an average severity of 7.2 ± 0.5 and at onset scores
of 1.8 ± 0.1 (Table 1 and Figure 1a). Compared with group II,
group I (colonies 1 to 3, Table 1) comprised the most suscep-
tible substrains, which developed arthritis earlier and with
greater severity than any other colonies. In contrast, group III
(colonies 10 and 11, Table 1) showed the least severe arthritis
(mean arthritis score of 3.0 ± 0.6) with delayed onset time (1.0
± 0.2), and approximately 30% of the immunized animals did
not have arthritis at the end of the experiment (Table 1 and Fig-
ure 1a). In arthritic animals, the histopathological abnormalities
(cellular infiltration, synovitis, pannus formation, and cartilage
and bone erosions) were similar to those (data not shown)
described earlier in numerous papers [7-9,20,28], and there
were no differences in the histopathology when peripheral
joints of any subcolonies with the same clinical scores [20]
were compared (data not shown).
Histopathology of the spine
A total of 127 spines were formalin-fixed, x-ray-imaged, and
then processed for histological analysis. Following the earlier
scoring system [10], IVD involvement was analyzed using
three parameters: (a) the cumulative spondyloarthropathy
score of each animal (Figure 1c), (b) the mean (IVD) inflamma-
tory score per animal (Figure 1d), and (c) the ratio of the
number of the inflamed IVDs per total number of IVDs
(expressed as a percentage) (Figure 1e). In the scoring of theAvailable online http://arthritis-research.com/content/11/1/R21
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127 spine sections, spondylitis was diagnosed in 62.2% of
BALB/c mice, which was significantly lower (P < 0.05) than
the mean of arthritis incidence (86.5%; n = 178). This obser-
vation confirmed that arthritis and spondylitis could occur
either together or separately in BALB/c mice [9] and that,
most likely, different genes of different QTLs control PGIA and
PGIS [9,29]. However, the most susceptible and most
severely arthritic BALB/c colonies (Table 1) showed the most
extensive spine involvement (Figure 1c–e) as assessed by
using any of the three spondylitis parameters listed above.
Similarly, animals that developed arthritis sooner exhibited
more progressive spondylitis (Figure 1b). Although no PGIS-
resistant BALB/c colony was found, there were large individ-
ual variations in the spine involvement. In addition, neighboring
IVDs of the same animal frequently showed different stages of
inflammation. Typically, the most affected spine segments
were the distal lumbar and distal cervical regions, whereas the
IVDs in the thoracic and proximal lumbar regions remained
less affected.
T cell- and B cell-mediated immune responses
Despite screening a wide spectrum of immunological parame-
ters, we could not identify 'colony-specific' cytokine, T-cell, or
B-cell responses. In vitro tests (T-cell proliferation and
cytokine production) showed evidence of T-cell activation in
response to PG stimulation, but T cell responses did not cor-
relate significantly with either arthritis or spondylitis scores.
Interestingly, female BALB/c mice of the Hollister and ByJ col-
onies (Table 1, colonies 10 and 11, group III), which were the
animals least susceptible to PGIA and PGIS, produced the
highest levels of anti-inflammatory IL-4, proinflammatory IL-6
and IFN-γ cytokines when assayed in spleen cultures. How-
ever, there was no evidence that any of these cytokine genes
(Figure 2) were expressed differentially in BALB/cJ versus
BALB/cByJ colonies (data not shown). We hypothesized that
BALB/c mice of the Hollister and ByJ 'low-susceptibility' colo-
nies (with delayed onset and less severe arthritis) still might be
in the initiative (proinflammatory) phase of arthritis at the end
of the experiments (days 63 and 64). This was supported by
the serum levels of autoantibodies to mouse PG (either IgG1
or IgG2a), which were significantly lower in animals of group
III than in any other colonies (data not shown). Indeed, in sup-
plemental experiments using age-matched females of The
Jackson Laboratory's BALB/cJ and BALB/cByJ colonies or of
Kingston and Hollister colonies of Charles River Laboratories,
Inc. (average versus low-susceptibility animals) injected with
the standard dose of 100 μg of PG protein on day 42 (third
Figure 1
Progression and severity of arthritis in 11 BALB/c colonies sorted into three different groups (listed in Table 1), correlation between the onset of  arthritis and spine involvement, and comparison of the three arthritic groups with different spine inflammation scores Progression and severity of arthritis in 11 BALB/c colonies sorted into three different groups (listed in Table 1), correlation between the onset of 
arthritis and spine involvement, and comparison of the three arthritic groups with different spine inflammation scores. (a) Each animal was scored for 
arthritis three times a week, and scores are shown as mean ± standard error of the mean. Arrow indicates the third injection, administrated on day 
42. Significant differences (P < 0.01), calculated by one-way analysis of variance, were found from day 32 between groups I, II, and III. (b) The ratio 
of the number of inflamed intervertebral discs (IVDs) per the total number of IVDs showed positive significant correlation (Pearson correlation coeffi-
cient ρ = 0.485; P < 0.0005) with the onset of arthritis. (c-e) Significant differences were found among the three arthritic groups when compared 
with three spine representative scores: cumulative spondylitis score (c), the mean spondylitis score (d), and the ratio of the number of inflamed IVDs 
per total number of IVDs (e). Asterisks indicate the level of significance between groups (*P < 0.05 and **P < 0.01) using Tamhane (c, e) (n = 127) 
and least significant difference (d) (n = 79) post hoc tests.Arthritis Research & Therapy    Vol 11 No 1    Farkas et al.
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Figure 2
Hierarchical clusterization comparing the 77 genes expressed differently at significant levels in spleen cells of naive and proteoglycan-immunized  (not-yet-arthritic) mice of BALB/cJ and BALB/cByJ colonies (n = 3 of each, four-group cross-comparison: naïve BALB/cJ versus immunized BALB/ cJ, naïve BALB/cByJ versus immunized BALB/cByJ, naïve BALB/cJ versus naïve BALB/cByJ, and immunized BALB/cJ versus immunized BALB/ cByJ) Hierarchical clusterization comparing the 77 genes expressed differently at significant levels in spleen cells of naive and proteoglycan-immunized 
(not-yet-arthritic) mice of BALB/cJ and BALB/cByJ colonies (n = 3 of each, four-group cross-comparison: naïve BALB/cJ versus immunized BALB/
cJ, naïve BALB/cByJ versus immunized BALB/cByJ, naïve BALB/cJ versus naïve BALB/cByJ, and immunized BALB/cJ versus immunized BALB/
cByJ). Color code indicates the normalized intensity expression values (with baseline transformation) on a logarithmic scale. Twenty-three genes 
showing over twofold differences in any of the four comparisons are labeled with asterisks. Whenever a gene name was not identified (n = 14), the 
original probe set ID (number_at), the Riken ID (numberRik), or the expressed sequence tag clone number is used. Those genes that showed signif-
icant differences only in response to immunization (n = 8) are labeled with the '†' symbol. Original data files are available via Gene Expression Omni-
bus (accession number [GEO:GSE13730] and National Center for Biotechnology Information tracking system number 15549466).Available online http://arthritis-research.com/content/11/1/R21
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immunization), these particular midterm differences disap-
peared (data not shown).
Relationship between immune responses and clinical 
features
Next, we compared arthritis- and spondylitis-'specific' immune
markers between the three groups of the clinical phenotypes
(Table 2). We compared serum antibody, cytokine, and anti-
gen-specific in vitro T-cell responses of 154 arthritic animals
with 24 immunized as-yet-non-arthritic mice (Table 2). The
incidence of PGIA in the three major groups was as follows:
98% in group I, 85% in group II, and 40% in group III. Although
there was a trend, we found that none of the in vitro-measured
T-cell activation markers (antigen-specific T-cell proliferation
and cytokine production) correlated significantly with the clin-
ical phenotype (severity) or histological results of arthritis. In
contrast, IgG1 and IgG2a (auto)antibodies were significantly
higher in arthritic than in non-arthritic animals (Table 2).
We also compared the in vitro antigen (PG)-specific T-cell
responses and serum antibody levels in mice having (n = 80)
or not having (n = 47) spondyloarthropathy. PG-stimulated
spleen cell cultures expressed significantly more IFN-γ in mice
without spondyloarthropathy than those that already had spine
inflammation (Table 2). In contrast, all antibody isotypes (either
to the immunizing human or autoantibodies to mouse cartilage
PG) were significantly higher in the spondyloarthopathic ani-
mals than in those having no spondylitis (Table 2).
Microarray results
Certain genetic differences between colonies of the same
murine strain have already been analyzed (for example, The
Jackson Laboratory detected 492 SNPs between BALB/cJ
and BALB/cByJ colonies, two sublines that were separated
about 73 years ago) [17]. Therefore, in one of our 'prototype'
experiments, we compared the gene expression profile of
splenocytes of these two colonies prior to, and then 12 days
after, the first PG injection, when the initial immune responses
are detectable but there is no arthritis. Figure 2 shows the
results of the analysis of 12 microarrays using three animals in
each group. All samples passed all quality control tests, and
36,816 probe sets were analyzed. As shown in the hierarchi-
cal clusterization panel, a total of 77 genes were expressed at
significantly different levels between naive and immunized
BALB/cJ and BALB/cByJ age-matched female mice. Twenty-
three genes showed greater than twofold differences (Figure
2), and 11 of the 77 genes were described as immune
response genes or associated with arthritis (Additional data
file 1) [30-65]. When we compared the 77 genes expressed
significantly in naïve and immunized mice, 69 were specific for
Table 2
Immunological differences between arthritic and non-arthritic animals as well as mice with or without spondylitis
Measured parameters Arthritic animals
(n = 154)
Non-arthritic animals
(n = 24)
Mice with spondylitis
(n = 80)
Mice without spondylitis
(n = 47)
In vitro T-cell proliferation, SI 2.96 ± 0.07 3.25 ± 0.13 3.00 ± 0.09 3.00 ± 0.14
In vitro IL-2 production (CTLL-2), SI 2.67 ± 0.07 2.73 ± 0.15 2.68 ± 0.10 2.66 ± 0.11
In vitro IL-4 production, ng/106 cells 2.65 ± 0.14 2.91 ± 0.34 2.79 ± 0.22 2.39 ± 0.18
In vitro IL-6 production, ng/106 cells 1.83 ± 0.01 2.17 ± 0.33 1.88 ± 0.14 1.86 ± 0.19
In vitro IFN-γ production, ng/106 cells 8.06 ± 0.28 8.50 ± 1.07 7.61 ± 0.37 9.56 ± 0.65a
In vitro TNF-α production, ng/106 cells 0.74 ± 0.01 0.77 ± 0.02 0.74 ± 0.01 0.75 ± 0.02
Serum IL-4, pg/mL 15.29 ± 2.41 22.80 ± 5.92 15.52 ± 3.32 18.49 ± 4.46
Serum IL-6, pg/mL 166.45 ± 20.21 106.18 ± 26.97 97.59 ± 14.94 65.05 ± 20.61
Serum IL-1β, pg/mL 96.36 ± 11.55 41.70 ± 11.29 163.78 ± 27.72 143.10 ± 31.16
Serum IFN-γ, pg/mL 26.14 ± 2.62 34.59 ± 6.27 25.05 ± 3.65 33.49 ± 4.55
IgG1 antibodies to human PG, mg/mL 12.75 ± 0.57b 8.30 ± 0.94 23.33 ± 0.78b 8.85 ± 0.86
IgG2a antibodies to human PG, mg/mL 1.36 ± 0.14a 0.72 ± 0.29 1.44 ± 0.21a 0.82 ± 0.17
IgG1 antibodies to PG, μg/mL 172.55 ± 13.47b 76.41 ± 10.56 174.99 ± 18.95a 116.68 ± 17.7
IgG2a antibodies to PG, μg/mL 68.01 ± 5.68b 24.79 ± 6.76 72.10 ± 8.18b 34.57 ± 6.16
All animals were immunized simultaneously with human cartilage proteoglycan in dimethyldioctadecyl-ammonium bromide. A total of three 
injections were given at 3-week intervals, and mice were sacrificed 3 weeks after the third injection (on days 63 and 64) when all in vitro assays 
were performed. Values represent mean ± standard error of the mean. Histological analysis was performed, and each inflamed intervertebral disc 
(IVD) was scored from '0' to '8' as described in Materials and methods. Positive (spondyloarthopathic) animals were combined if at least one IVD 
was affected with inflammation. Superscript letters indicate the level of significance (aP < 0.05 and bP < 0.01) between arthritic and non-arthritic 
animals or between mice with or without spondylitis. IFN-γ, interferon-gamma; IL, interleukin; PG, proteoglycan; SI, stimulation index; TNF-α, tumor 
necrosis factor-alpha.Arthritis Research & Therapy    Vol 11 No 1    Farkas et al.
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naïve and only 8 genes were associated with the immunization
(Figure 2) (Gene Expression Omnibus accession number
[GEO:GSE13730] and National Center for Biotechnology
Information tracking system number 15549466).
Discussion
Although female BALB/c mice are close to 100% susceptible
to PG-induced arthritis after three consecutive immunizations
with human cartilage PG aggrecan [7,18,66], we found signif-
icant differences in arthritis severity, onset, and progression
among the inbred colonies. Our findings, however, do not indi-
cate that animals in group III acquired resistance; rather, these
mice showed a tendency to develop arthritis, but they needed
a longer period of time, a higher dose of antigen, or an addi-
tional (fourth) injection of human PG. Similar results were
found when F2 hybrid mice of susceptible BALB/c and resist-
ant strains were immunized and tested for arthritis- or spondy-
loarthropathy-associated QTLs using the same antigen,
immunization protocol, and scoring system (visual and histol-
ogy) and when MHC- and age-matched animals were housed
in the same room, occasionally for more than half a year
[9,11,23,24,29,66]. These genome-wide screening studies
explored overlapping QTLs in different genetic combinations
between high- or low-susceptibility F2 hybrids, indicating that
different combinations of genes may affect disease onset and/
or severity [9,24,29]. In this comparative study, differences
among different colonies suggest that either as-yet-unknown
genetic factors or differences in transforming environmental
effects at the site of origin and/or our animal facility (although
both are pathogen-free) caused these unexpected findings.
Some of the most important environmental factors are the nor-
mal intestinal microbial flora and various bacterial cell wall
components (for example, peptidoglycans) [67], which may
affect the phenotype (onset and/or severity) of arthritis.
Although a variation in the composition of normal bacterial
flora can explain some of our findings, we have not had a
chance yet to investigate intestinal flora-related differences in
detail in the 11 BALB/c colonies.
Certain BALB/c substrains are known for the production of
plasmacytoma in response to mineral oil injection [68], which
generated a myeloma cell line (Sp2/0.Ag.14), a fusion partner
with lymphoblasts routinely used in monoclonal antibody tech-
nology [69]. Moreover, though not frequently (in less than 2%
of retired breeder female BALB/c mice and, so far, only in the
NCI/Kingston colony), we observed spontaneous arthritis with
less or more extensive synovitis and inflammation (T.T. Glant
and K. Mikecz, unpublished observation), occasionally associ-
ated with cartilage erosion in small peripheral joints, which are
histology features that were indistinguishable from those seen
in PGIA (unpublished observation).
Although the dominant genetic factor is the MHC in both RA
and PGIA, the MHC alone is insufficient to affect arthritis sus-
ceptibility and severity (for example, in H-2d DBA/2 mice) [9].
Two 'Q' subloci (Q6 and Q8) were expressed at a significantly
higher level in BALB/cJ mice than in BALB/cByJ mice (Figure
2 and Additional data file 1), which might contribute to the ear-
lier onset or more severe arthritis in BALB/cJ mice, but none
of these subloci was associated with the immunized state (in
Figure 2, see naïve versus immunized pairwise comparisons of
the two subcolonies). Another critical factor in the pathogene-
sis of PGIA is the non-MHC genetic component (reviewed in
[9,70]). The first albino mouse was found by a pet dealer in
Ohio in 1913 [71]. Brothers and sisters were systematically
mated and an inbred colony was established in 1920 [71].
The original BALB/c colony was separated in 1935. One of
these colonies was maintained by G. Snell at The Jackson
Laboratory (BALB/c J), and the other was maintained by H.B.
Andervont (BALB/c AnN) and then transferred to the National
Institutes of Health (NIH) (Bethesda, MD, USA) in 1951 [72].
All other BALB/c colonies are derived from these two ancient
ancestors. Charles River Laboratories, Inc., started breeding
BALB/c mice in 1974 (mice from NIH), Harlan Laboratories,
Inc., (Indianapolis, IN, USA) in 1986 (mice from NIH), and
Taconic Farms, Inc. (Hudson, NY, USA) in 1988 (mice were
purchased from the NIH). It is also relevant to note that, except
for one BALB/c colony (Hollister, CA, USA), all of the distrib-
utors are located on the East Coast or in the Midwest regions
of the US. During their 88-year history, inbred BALB/c colo-
nies have been exposed to various environmental effects (mov-
ing to another location, repopulation from other colonies due
to fire, and so on). Although the companies ensure the genetic
homogeneity of the colonies by applying strict breeding and
maintenance rules, differences among the colonies do occur.
Historically, the BALB/cJ colony represents the original BALB/
c mice of The Jackson Laboratory (maintained since 1935),
whereas the BALB/cByJ mice were inherited from the NIH and
the breeding stock was transferred to The Jackson Laboratory
in 1967, when D.W. Bailey joined the company. The two colo-
nies have been maintained separately and represent the pedi-
gree of the two original BALB/c lines (The Jackson Laboratory
versus NIH). Therefore, the 492 SNPs [17] and the 77 differ-
entially expressed genes (Figure 2) of the two colonies attest
to the dynamic flexibility of the mammalian (mouse) genome,
which keeps changing despite being exposed to comparable
environmental conditions.
Thirty-three of the 492 SNPs and 11 genes (labeled in yellow
in Additional data file 1) of the 77 differentially expressed
genes in BALB/cJ and BALB/cByJ mice are related to immune
regulatory functions, which in turn may affect arthritis onset,
severity, and susceptibility. Although most of the SNPs are
present in intron sequences, some of them may have an effect
on exon splicing. However, the differences in the phenotypes
can hardly be explained by the SNPs and the few immunoreg-
ulatory genes that are expressed differentially in both naïve and
immunized BALB/cJ and BALB/cByJ mice. Similarly, 8 of theAvailable online http://arthritis-research.com/content/11/1/R21
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77 genes showed differential expression (either upregulation
or downregulation) in response to immunization (Figure 2,
labeled with the '†' symbol). Although we can speculate that
these genes are involved in arthritis severity or onset, probably
none of them is responsible for susceptibility.
An important observation was the inflammation around the IVD
in arthritic BALB/c mice, which is found in up to 60% of
patients with ankylosing spondylitis when examined by mag-
netic resonance imaging [73]. The nucleus pulposus of IVDs
is composed mostly of hyaluronan and 'cartilage-specific' PG
aggrecan, and the core protein of the human aggrecan mole-
cule has over 100 predicted and at least 27 confirmed T-cell
epitopes in BALB/c mice [9,74]. A number of these epitopes
have been reported as dominant/arthritogenic in wild-type or
humanized BALB/c mice [74-78] and are possibly involved in
immune reactions to IVD components. The immune attack,
characterized by a predominantly lymphocytic infiltration
around the IVD in the early phase of the spondylitis [7-9], is
most likely elicited by cross-recognition of IVD PG in mice
immunized with human PG. Spondyloarthropathy has a pro-
gressive character and shows a correlation with the onset and
progression of peripheral arthritis, although PGIA and PGIS
are two independent diseases [11], as we have shown, and
different genes in different QTLs control PGIA [9] and PGIS
[29]. Interestingly, although inflammatory (autoimmune)
spondyloarthropathy occurs only in BALB/c and C3H mice
[7,8,11], spontaneous or experimentally induced disc degen-
eration has been reported in numerous animal models [79-82].
Autoimmune mechanisms are thought to play a major role only
in HLA-B27 transgenic rodents [83-85] and in PGIA [7,9].
We expected to find robust T- and B-cell responses in vitro in
antigen (PG)-stimulated spleen cell cultures of arthritic mice
because RA is thought to be a T cell-dependent and B cell-
mediated disease [86]. Due to the intense involvement of var-
ious lymphoid organs (spleen and lymph nodes) in the regula-
tion of immune responses, the serum cytokine levels may
represent a momentary status rather than a general level of in
vivo activation [87]. In this respect, it is not surprising that we
could not find significant correlations between clinical or his-
tological findings and serum cytokine levels. On the other
hand, when we analyzed and compared the results of individ-
ual animals with or without arthritis or spondylitis at the end of
the observation period (that is, without pooling animals within
a group [colony]), significant correlations were found (Table
2). For example, significantly higher levels of heteroantibodies
and autoantibodies to cartilage PG were measured in the sera
of arthritic and spondyloarthopathic animals than in as-yet-
non-affected cage-mates (Table 2). An example of negative
correlation was found when we compared PG-specific in vitro
IFN-γ production by spleen cells in animals with and without
spondylitis (Table 2), perhaps suggesting that Th1 T-cell acti-
vation was still restricted to the lymphoid organs before the
immune attack against the spine occurred. Similar differences
and/or negative-positive correlations, though at lower levels,
were found when other markers were compared with the clin-
ical phenotype.
Both RA and PGIA require T cells and B cells (or autoantibod-
ies), in which the autoimmune attack culminates in the inflam-
matory destruction of peripheral joints. A number of similarities
between RA and PGIA suggest that certain as-yet-unknown
alterations of the immune system exist in both humans and
mice. As a continuation of the experiments presented in this
study, we are comparing gene expression in various lymphoid
organs, and joint tissues of representative colonies at different
time points after immunization, and correlating these results
with clinical phenotypes of arthritis and spondylitis as well as
with the results of our earlier genome-wide studies [9].
Conclusion
The MHC (H-2d) and non-MHC components of the genetic
background make the BALB/c strain highly susceptible to
inflammatory arthritis and spondylitis. Although BALB/c colo-
nies uniformly develop PGIA (> 95%) and PGIS (> 80%) in
response to immunization with human cartilage PG aggrecan,
even in the absence of mycobacterial components (that is,
without the use of Freund's complete adjuvant), there are sig-
nificant differences among BALB/c colonies maintained even
by the same vendor at different locations or when the 'subcol-
onies' were separated several decades ago. Technically,
among the BALB/c colonies tested so far, we have not found
a PGIA- or PGIS-resistant colony, but the 'level of susceptibil-
ity' is different among them. This may be a critical question
when laboratories use different colonies to induce other dis-
eases, PGIA or PGIS, or when transgenic/gene-deficient mice
in 'different' BALB/c backgrounds are compared with control
wild-type BALB/c animals. Although this observation may be
'specific' for BALB/c colonies, or PGIA and PGIS, this might
not be a correct conclusion. A mutation in critical genes may
dramatically affect cell function(s), and the result of the muta-
tion is then designated as a 'new phenotype'. However, muta-
tions in inbred colonies occur frequently (for example, C5
deficiency in DBA/2 mice [88,89], in the cytoplasmic domain
of Toll-like receptor-4 of The Jackson Laboratory's C3H/HeJ
colony [90], and in the Ptpn6 gene of motheaten mice [91,92],
and so on). Relatively small or as-yet-unidentified mutations in
the genome may significantly affect disease susceptibility or
eventually a series of physiological/pathophysiological func-
tions, preferentially leading to incorrect conclusions.
Genetic components are major players in the development of
PGIA, and our genome-wide studies explored close to 30 dif-
ferent loci (12 corresponding to human RA susceptibility loci
identified in familial studies) [9]. Here, we present the results
of a systemic age- and gender-matched comparative study
using 11 substrains/colonies of BALB/c mice. With a subop-
timal dose of arthritogenic cartilage PG, significant differences
were found in arthritis susceptibility among colonies. AlthoughArthritis Research & Therapy    Vol 11 No 1    Farkas et al.
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no single gene or 'biomarker' that could account for these dif-
ferences has been identified, the large number of SNPs in two
sister colonies (The Jackson Laboratory's BALB/cJ and BALB/
cByJ) separated about 70 years ago and the corresponding
microarray results indicate that, indeed, a single or a limited
number of mutations may dramatically affect the clinical phe-
notype of arthritis in BALB/c mice. The differences identified
among colonies may help us to target disease-affecting
gene(s) and may become nearly as valuable a tool as subcon-
genic approaches. The results of our study may serve as a
direction toward a more accurate selection of disease-control-
ling genes from previously identified QTLs, especially from
those that are shared in RA and corresponding animal models.
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